HR 4438 United States House · 118th Congress

John W. Walsh Alpha-1 Home Infusion Act of 2023

This bill expands Medicare coverage to include home infusion treatment for people with Alpha-1 Antitrypsin Deficiency Disorder, a genetic condition causing lung and liver damage. It specifically covers "augmentation therapy" (a standard treatment using Alpha-1 Proteinase Inhibitor) when administered in a patient's home by qualified providers. Medicare will pay 80% of the cost for intravenous kits and up to 2 hours of nursing care during these home infusions, starting January 1, 2025. The change directly affects Medicare beneficiaries with this condition who require home-based treatment and their qualified home infusion providers.

Issues: ✓ Healthcare

Bill status in committee 1 of 4 stages cleared

Introduction

Jun 2023

Committee Review

Floor Vote

President

Introduced Jun 30, 2023 Last action Dec 17, 2024

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Dec 17, 2024

Committee

Referred to the Subcommittee on Health.

lower

Jul 7, 2023

Committee

Referred to the Subcommittee on Health.

lower

Jun 30, 2023

Committee

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

lower

Jun 30, 2023

Introduced

Introduced in House

lower

1 primary · 59 co-sponsors